Yungan TAO
@YG_TAO
Followers
356
Following
326
Media
6
Statuses
259
Radiation Oncologist, Gustave Roussy Cancer Campus President-Elect GORTEC - French Head and Neck Oncology Radiotherapy Group
Paris
Joined October 2016
Pembrolizumab (before surgery and during post-operative radiotherapy + after RT) approved in CPS>=1 resectable LA-HNSCC
0
0
1
RT @PBlanchardMD: Hot of the press @IJROBP: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial . Full text her….
0
65
0
RT @PBlanchardMD: GORTEC announces that the NIVOPOSTOP study (NCT03576417) met its primary endpoint of Disease-Free survival (DFS) across a….
0
25
0
Honored to contribute as co-PI to our Phase 3 trial NIVOPOSTOP GORTEC 2018-01 evaluating nivolumab in addition to post-operative concurrent CRT for resected HR LAHNSCC pts, which met its primary endpoint of DFS across all comers. @PBlanchardMD @GustaveRoussy.
4
9
32
KN689 is the 1st +ve trial IO (+surgery -RT) in LA-HNSCC, neoadjuvant role PD-1 probably essential, but we should not ignore CONCOMITANT use of pembro during post-OP (C)RT. Waiting for GORTEC Nivo-postOP results to clarify definitely neoadjuvant role.
KN689 positive, Neoadjuvant pembrolizumab 2 cycles before surgery improved EFS compared to surgery in LA-HNSCC! @PBlanchardMD @DrMLChua.
0
1
9
KN689 positive, Neoadjuvant pembrolizumab 2 cycles before surgery improved EFS compared to surgery in LA-HNSCC! @PBlanchardMD @DrMLChua.
2
6
13
Toripalimab, anti-PD-1 of TopAlliance finally approved by EMA for 1L R/M nasophayrgeal cancer and also 1L esophageal SCC. @PBlanchardMD @DrMLChua.
1
0
3
RT @OncLive: Wrapped another great interview with @YG_TAO of @GustaveRoussy who walked us through data from the final analysis of the phase….
0
3
0
Thank you @DrMLChua , surely synergy Avelumab+cetuximab on distant control, and a little + tox during RT. Difficult to say no synergy anti-PD-1 (PD-L1) + cDDP, waiting for long-term outcome KeyNote-412 next ASCO. Still KeyNote-689 and GORTEC 2018-01 Nivo-postOP very soon.
Interesting final data of the GORTEC REACH trial presented by @YG_TAO #ESMO2024 . Is the diff in fit vs unfit patients with #headneckcancer indicative of synergy between anti-EGFR and anti-PDL1 BUT not CDDP and anti-PDL1 or just more tx in unfit patients? 🧐. @KaramLab
0
1
6
0
2
0
RT @PBlanchardMD: Innovative GORTEC trial at #ESMO2024: prophylactic neck #radiotherapy replaced by IO durvalumab. Low rate of neck relap….
0
18
0
OS result of keynote A18 confirmed the benefit of pembrolizumab when combining with concurrent chemo- radiotherapy, in contrast to our negative results of IO + RT in HNSCC @PBlanchardMD @DrMLChua
0
0
4
RT @PBlanchardMD: Congrats to my friend @YG_TAO & GORTEC for this huge trial of IO in LA HNSCC. Avelumab-cetuximab inferior to cisplatin CR….
0
29
0
Big PFS gain with HR 0.51 in favor of Ivonescimab (AK112) vs Pembro 1L NSCLC compared with HR 0.78 in LEAP-007 Pembrolizumab +/- Lenvatinib, could we expect OS gain? Hope AK112 also in HNSCC @PBlanchardMD.
💥 The end of Pembro reign? .Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: HARMONi-2 #WCLC24 #LCSM
0
1
4
Another disappointing result of combination IO and RT, even with SBRT. While huge benefit in phase 2 trial. Similar situation as Trilynx with IAPi in LA-HNSCC. @PBlanchardMD @BenjaminBesseMD.
0
1
5
Totally agree, OS similar, it is possible to use the osimertinib later without OS loss.
LIFETIME osimertinib after a treatment with curative intent?.In pts with EGFRmut stage III NSCLC, chemo-radiotherapy can CURE pts. Were pts in LAURA properly staged by petscan/brain RMI?.Why not using MRD to select patient?.Strong concerns when OS is not positive. #ASCO24
0
0
4
Bispecific PD-1/VEGF antibody Ivonescimab (AK112) showed better PFS than pembrolizumab in 1L NSCLC TPS>=1, first head-to-head trial vs anti-PD-1 ICI, waiting for OS result. Trial with AK112 in HNSCC expected. @dplanchard @PBlanchardMD.
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China.
0
0
5
More details will be interesting: whether concur/adjuv Nivo non-inferior to or worse than adjuv Durva? Not same negative as Pacific 2 (Durva vs placebo). @PBlanchardMD @BenjaminBesseMD .Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
0
0
4